已收盤 11-20 16:00:00 美东时间
-0.070
-5.19%
今日重点评级关注:韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从42美元升至44美元;HC Wainwright & Co.:维持WhiteFiber"买入"评级,目标价从34美元升至36美元
11-12 19:19
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $25 to $20.
11-11 22:37
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 28.13 percent increase over losses of $(0.64) per share from the same period last year.
11-11 02:41
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 21.31 percent increase over losses of $(0.61) per share from the same period last year.
08-11 20:03
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced expanded data from its Phase 1a single ascending dose trial evaluating TH103 for the treatment of neovascular age-related macular degeneration. Following the announcement, the stock jumped nearly 18%. The clinical-stage biopharmaceutical company sta...
07-18 01:31
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July 17...
07-17 19:02
TD Cowen analyst Tara Bancroft initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Buy rating.
06-16 00:45
今日重点评级关注:HC Wainwright & Co.:维持Autolus Therapeutics"买入"评级,目标价从9美元升至10美元;Maxim Group:维持Rezolute"买入"评级,目标价从4美元升至10美元
05-15 10:49
今日重点评级关注:瑞杰金融:上调InflaRx评级至"强烈买入",目标价从7美元升至9美元;巴克莱:维持Orchestra BioMed Hldgs"超配"评级,目标价从12美元升至13美元
05-14 14:32
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $26 to $25.
05-13 22:24